First Quarter 2001 Performance

• Income From Continuing Operations Increased 16%

• Diluted Earnings Per Share From Continuing Operations up 15%

• Worldwide Human Pharmaceutical Net Revenue Rose 12%

Previous slide

Next slide

Back to first slide

View graphic version